{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:56Z","timestamp":1793727896073,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-MSX0219"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0219"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["YXQN202440"],"award-info":[{"award-number":["YXQN202440"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["202417-42"],"award-info":[{"award-number":["202417-42"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502501"],"award-info":[{"award-number":["2022YFC2502501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32030054"],"award-info":[{"award-number":["32030054"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20415"],"award-info":[{"award-number":["U23A20415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000539"],"award-info":[{"award-number":["82000539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.gendis.2025.101761","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:47:08Z","timestamp":1751572028000},"page":"101761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Tirzepatide, a dual GIP\/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-0626","authenticated-orcid":false,"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1916-0031","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong Z.","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gendis.2025.101761_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2025.101761_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10295","key":"10.1016\/j.gendis.2025.101761_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.gendis.2025.101761_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(22)00077-8","volume":"10","author":"Battelino","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10300","key":"10.1016\/j.gendis.2025.101761_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.gendis.2025.101761_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.101761_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial [published correction appears in JAMA. 2024 Aug 20;332(7):595.]","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib14","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gendis.2025.101761_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155248","article-title":"Recent guidelines for non-alcoholic fatty liver disease (NAFLD)\/fatty liver disease (FLD): are they already outdated and in need of supplementation?","volume":"136","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-024-02416-2","article-title":"Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics","volume":"24","author":"Liang","year":"2025","journal-title":"Lipids Health Dis"},{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.gendis.2025.101761_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gendis.2025.101761_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1309024","article-title":"Human lipocalins bind and export fatty acids through the secretory pathway of yeast cells","volume":"14","author":"Ekim Kocabey","year":"2024","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1194\/jlr.M090969","article-title":"CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway","volume":"60","author":"Li","year":"2019","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.gendis.2025.101761_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrneph.2017.126","article-title":"CD36 in chronic kidney disease: novel insights and therapeutic opportunities","volume":"13","author":"Yang","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101761_bib23","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1172\/JCI99315","article-title":"Endothelial cell CD36 optimizes tissue fatty acid uptake","volume":"128","author":"Son","year":"2018","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.gendis.2022.12.003","article-title":"CD36 promotes tubular ferroptosis by regulating the ubiquitination of FSP1 in acute kidney injury","volume":"11","author":"Ma","year":"2023","journal-title":"Genes Dis"},{"issue":"2","key":"10.1016\/j.gendis.2025.101761_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/db14-0582","article-title":"Regulation of AMPK activation by CD36 links fatty acid uptake to \u03b2-oxidation","volume":"64","author":"Samovski","year":"2015","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1748-1716.2008.01878.x","article-title":"Contribution of FAT\/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview","volume":"194","author":"Holloway","year":"2008","journal-title":"Acta Physiol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101761_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.gendis.2025.101761_bib28","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2023-331401","article-title":"MASH resolution index: development and validation of a non-invasive score to detect histological resolution of MASH","volume":"73","author":"Loomba","year":"2024","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.gendis.2025.101761_bib29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101761_bib30","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.gendis.2025.101761_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.gendis.2025.101761_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101957","article-title":"Suppression of hepatic ChREBP\u237a-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD\/MASH","volume":"85","author":"Zhang","year":"2024","journal-title":"Mol Metabol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101761_bib34","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.cmet.2024.07.023","article-title":"Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease","volume":"36","author":"Petersen","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2016.06.005","article-title":"Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy","volume":"24","author":"Petersen","year":"2016","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"Jeon","year":"2020","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/FJC.0000000000000087","article-title":"GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A","volume":"64","author":"Dai","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.gendis.2025.101761_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6237405","article-title":"Mechanism of GLP-1 receptor agonists-mediated attenuation of palmitic acid-induced lipotoxicity in L6 myoblasts","volume":"2022","author":"Kong","year":"2022","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.gendis.2025.101761_bib39","article-title":"Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.gendis.2025.101761_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104778","article-title":"Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis","volume":"156","author":"Su","year":"2020","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.101761_bib41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1159\/000478872","article-title":"GLP-1\/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis","volume":"42","author":"Chen","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"10.1016\/j.gendis.2025.101761_bib42","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bbalip.2018.10.008","article-title":"Of mice and men: the physiological role of adipose triglyceride lipase (ATGL)","volume":"1864","author":"Schreiber","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hep.32112","article-title":"Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase\/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice","volume":"75","author":"Fuchs","year":"2022","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gendis.2025.101761_bib44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2024.09.037","article-title":"Inhibition of ATGL alleviates MASH via impaired PPAR\u03b1 signalling that favours hydrophilic bile acid composition in mice","volume":"82","author":"Dixon","year":"2025","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101761_bib45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00011.2023","article-title":"CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease","volume":"104","author":"Glatz","year":"2024","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.gendis.2025.101761_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/jcm12010318","article-title":"FAT\/CD36 participation in human skeletal muscle lipid metabolism: a systematic review","volume":"12","author":"Ramos-Jim\u00e9nez","year":"2022","journal-title":"J Clin Med"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225002508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225002508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:10:15Z","timestamp":1762618215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225002508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2352304225002508"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101761","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide, a dual GIP\/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd\u00e9","name":"copyright","label":"Copyright"}],"article-number":"101761"}}